Rheumatoid arthritis and Superficial spreading melanoma stage unspecified
Summary:
Superficial spreading melanoma stage unspecified is found among people with Rheumatoid arthritis, especially for people who are female, 60+ old.
The study analyzes which people have Superficial spreading melanoma stage unspecified with Rheumatoid arthritis. It is created by eHealthMe based on reports of 29 people who have Rheumatoid arthritis from the Food and Drug Administration (FDA), and is updated regularly. You can use the study as a second opinion to make health care decisions.
What is Rheumatoid arthritis?
Rheumatoid arthritis (a chronic progressive disease causing inflammation in the joints) is found to be associated with 1,679 drugs and 2,122 conditions by eHealthMe. Check the latest studies of Rheumatoid arthritis.
What is Superficial spreading melanoma stage unspecified?
Superficial spreading melanoma stage unspecified (superficial spreading cancer stage unspecified) is found to be associated with 35 drugs and 83 conditions by eHealthMe. Check the latest studies of Superficial spreading melanoma stage unspecified.
29 people who have Rheumatoid Arthritis and Superficial Spreading Melanoma Stage Unspecified are studied.

Gender of people who have Rheumatoid Arthritis and experienced Superficial Spreading Melanoma Stage Unspecified *:
- female: 79.31 %
- male: 20.69 %
Age of people who have Rheumatoid Arthritis and experienced Superficial Spreading Melanoma Stage Unspecified *:
- 0-1: 0.0 %
- 2-9: 0.0 %
- 10-19: 0.0 %
- 20-29: 0.0 %
- 30-39: 0.0 %
- 40-49: 9.09 %
- 50-59: 4.55 %
- 60+: 86.36 %
Common co-existing conditions for these people *:
- Polyarthritis (arthritis which involves 5 or more joints simultaneously): 4 people, 13.79%
- Psoriasis (immune-mediated disease that affects the skin): 1 person, 3.45%
- Malignant Melanoma (skin cancer rises from melancytes): 1 person, 3.45%
- High Blood Pressure: 1 person, 3.45%
- Herpes Zoster: 1 person, 3.45%
- Gastritis (inflammation of stomach): 1 person, 3.45%
Common drugs taken by these people *:
- Remicade: 9 people, 31.03%
- Orencia: 8 people, 27.59%
- Enbrel: 7 people, 24.14%
- Methotrexate: 5 people, 17.24%
- Acetaminophen: 4 people, 13.79%
- Arava: 3 people, 10.34%
- Calcium Carbonate: 3 people, 10.34%
- Folacin: 3 people, 10.34%
- Humira: 3 people, 10.34%
- Ibuprofen: 3 people, 10.34%
Common symptoms for these people *:
- Waldenstrom's Macroglobulinaemia (cancer affects small lymphocytes (white blood cells)): 2 people, 6.90%
- Lichen Planus (an inflammatory skin condition, characterized by an itchy, non-infectious rash): 2 people, 6.90%
- Infusion Related Reaction: 2 people, 6.90%
- Psoriasis (immune-mediated disease that affects the skin): 1 person, 3.45%
- High Blood Pressure: 1 person, 3.45%
- Bronchitis (inflammation of the mucous membrane in the bronchial tubes): 1 person, 3.45%
- Bursitis (inflammation of a bursa, typically one in the knee, elbow, or shoulder): 1 person, 3.45%
- Bursitis Infective Staphylococcal (staphylococcal infection of the subacromial/subdeltoid bursa): 1 person, 3.45%
- Chest X-Ray Abnormal: 1 person, 3.45%
- Cholestasis (a condition where bile cannot flow from the liver to the duodenum): 1 person, 3.45%
* Approximation only. Some reports may have incomplete information.
Do you take medications and have Superficial spreading melanoma stage unspecified?
- Check whether Superficial spreading melanoma stage unspecified is associated with a drug or a conditionRelated publications that referenced our studies
- Mathai, P. C., Andrade, N. N., Aggarwal, N., Nerurkar, S., & Kapoor, P. , "Low-dose methotrexate in rheumatoid arthritis: a potential risk factor for bisphosphonate-induced osteonecrosis of the jaw", Oral and maxillofacial surgery, 2018 Jan .
- Azuma N, Matsui K, Hashimoto N, Yoshikawa T, Sano H, "Successful Switch to Golimumab for Eosinophilia and Skin Symptoms Related to Multiple Biologics in a Patient with Rheumatoid Arthritis", Internal Medicine, 2017 Jun .
- Saif MW, "Rheumatoid arthritis associated with the use of Sandostatin? LAR? depot in a patient with pancreatic neuroendocrine tumor", An association or a coincidence? The first case report, 2017 Jan .
- Ahmed AB, Radwan AM, Baddary HM, "Prevalence of Generalized Anxiety Disorder in Patients with Rheumatoid Arthritis and its Relationship with Disease Activity", The Egyptian Journal of Hospital Medicine, 2016 Jan .
- Mathai, P. C., Andrade, N. N., Aggarwal, N., Nerurkar, S., & Kapoor, P. , "Low-dose methotrexate in rheumatoid arthritis: a potential risk factor for bisphosphonate-induced osteonecrosis of the jaw", Oral and maxillofacial surgery, 2018 Jan .
- Azuma N, Matsui K, Hashimoto N, Yoshikawa T, Sano H, "Successful Switch to Golimumab for Eosinophilia and Skin Symptoms Related to Multiple Biologics in a Patient with Rheumatoid Arthritis", Internal Medicine, 2017 Jun .
- Saif MW, "Rheumatoid arthritis associated with the use of Sandostatin? LAR? depot in a patient with pancreatic neuroendocrine tumor", An association or a coincidence? The first case report, 2017 Jan .
- Ahmed AB, Radwan AM, Baddary HM, "Prevalence of Generalized Anxiety Disorder in Patients with Rheumatoid Arthritis and its Relationship with Disease Activity", The Egyptian Journal of Hospital Medicine, 2016 Jan .
Related studies:
Treatments, associated drugs and conditions:
- Rheumatoid arthritis (1,091,833 reports)
- Superficial spreading melanoma stage unspecified (339 reports)
All the drugs that are associated with Superficial spreading melanoma stage unspecified:
All the conditions that are associated with Superficial spreading melanoma stage unspecified:
- Superficial spreading melanoma stage unspecified (83 conditions)
How the study uses the data?
How to use the study?
DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.
The study is based on Superficial spreading melanoma stage unspecified and Rheumatoid arthritis, and their synonyms.
Who is eHealthMe?
With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Ear Pain and Tinnitus - 3 seconds ago
- Could Arava cause Hypertonic Bladder? - 10 seconds ago
- Drug interactions of Flovent Hfa and Seroquel - 11 seconds ago
- Could Aranesp cause Acute Kidney Failure? - 12 seconds ago
- Could Arava cause Hepatic Function Abnormal? - 12 seconds ago
- Hiv Infection and Polymyositis - 26 seconds ago
- Drug interactions of Claritin and Fuzeon - 27 seconds ago
- Drug interactions of Ribavirin and Rifaximin - 34 seconds ago
- Could Celecoxib cause Muscle Atrophy? - 37 seconds ago
- Drug interactions of Whey and Vitamin B6 - 42 seconds ago